Working… Menu

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00149617
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : October 9, 2015
National Institute on Drug Abuse (NIDA)
Information provided by:
Medical University of South Carolina

Brief Summary:
This study will assess the effectiveness of a combination of buspirone and motivational interviewing therapy in the treatment of marijuana dependence.

Condition or disease Intervention/treatment Phase
Marijuana Abuse Mood Disorders Drug: Buspirone Phase 2

Detailed Description:

Marijuana dependence is one of the most common substance-related disorders in the United States. Despite its prevalence, there is a lack of clinical research addressing treatments for marijuana dependence. Research has shown that marijuana abuse is associated with affective disorders. This may be caused by repeated use for relief from anxiety. The use of an anxiolytic agent, a drug that relieves anxiety, may help treat marijuana dependence. Motivational enhancement therapy has been shown to reduce marijuana use. Therefore, it is likely that buspirone, which is an anxiolytic agent, combined with motivational enhancement therapy will prove beneficial in treating marijuana dependence. This study will assess the effectiveness of a combination of buspirone and motivational interviewing in the treatment of marijuana dependence.

This double-blind study will last a total of 16 weeks. Participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks. There will be one follow-up appointment 4 weeks post-intervention. Baseline assessments will include a physical exam and urine and blood tests. Study visits will occur weekly throughout treatment in order to monitor compliance, assess adverse affects, and obtain substance use data. Mood assessment scales, marijuana craving questionnaires, and a withdrawal symptom checklist will be used to gather the data. Urine drug screens will be collected weekly to test for marijuana use. In addition to this, the presence of opioids, cocaine, amphetamines, and benzodiazepines will be tested at baseline, Weeks 6 and 12, and at follow-up. A 10-day supply of medication will be dispensed to participants each week. Meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline, Week 2, and Week 4. Participants' perceived quality of life will be measured at baseline and Weeks 6 and 12 to determine the effect of buspirone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Career Training in Marijuana Dependence
Study Start Date : April 2004
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Drug use; measured at Weeks 12 and 16

Secondary Outcome Measures :
  1. Anxiety; measured at Week 12
  2. Craving; measured at Week 12
  3. Withdrawal symptoms; measured at Week 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets DSM-IV criteria for marijuana dependence
  • Lives within 60 miles of the study site
  • Willing to provide collateral individuals for contact purposes
  • Willing to use an effective form of contraception throughout the study

Exclusion Criteria:

  • Meets DSM-IV criteria for dependence upon a substance other than marijuana, nicotine, or caffeine
  • Meets DSM-IV criteria for a history of schizophrenia or another non-affective psychotic disorder or bipolar disorder
  • Meets DSM-IV criteria for current major depressive disorder or eating disorder
  • Significant cognitive impairment
  • Currently taking benzodiazepines, antidepressant, or antipsychotic medications
  • Major medical illnesses (e.g., HIV, kidney failure, unstable angina, chronic obstructive pulmonary disease, infectious hepatitis)
  • Not in stable housing
  • Pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00149617

Layout table for location information
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Aimee Mcrae, Pharm.D. Medical University of South Carolina
Layout table for additonal information
Responsible Party: Aimee L. McRae, Medical University of South Carolina Identifier: NCT00149617    
Other Study ID Numbers: NIDA-15440-1
K23DA015440 ( U.S. NIH Grant/Contract )
First Posted: September 8, 2005    Key Record Dates
Last Update Posted: October 9, 2015
Last Verified: December 2007
Keywords provided by Medical University of South Carolina:
Mood Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Mood Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action